With an impressive CAGR from 2020 to 2026, the Peptide Cancer Vaccine market revenue increased from Million USD in 2016 to Million USD in 2020 and will reach Multi Million USD in 2026.
The rise in cancer cases, advancements in technology, new cancer treatments, government funding increases, the ageing population, and the selectivity and long-lasting effects of peptide cancer vaccines are the main factors driving the global market for these vaccines. The ease of synthesis, affordability, and convenience of peptide cancer vaccines, as well as their use in clinical settings, adaptability to changing antigens, and reduced risk of anaphylaxis caused by antigens, are anticipated to drive the market forward in the near future. Peptide-based vaccines are excellent alternatives to conventional immunisation methods since chemical modifications can be incorporated with relative ease. It is possible to modify peptide-based vaccinations to produce more stable peptide mimotopes, enabling targeted distribution of vaccine components with predictable peptide length and chemical integrity.
Leading Companies in the Peptide Cancer Vaccine Industry:
1. TapImmune: Established in 1991. Headquarters in the United States. Creator of cancer immunotherapies that focus on both metastatic illness and tumours. With the help of the company's cancer immunotherapies, women can strengthen their immune systems and ward off ovarian and breast cancer by using over-the-counter vaccines to comprehensively stimulate both killer T-cells and helper T-cells to attack cancer cells. Marker Therapeutics, a company in T-cell treatment, and TapImmune intend to merge.
2. Merck: Established in 1891. German headquarters are in Darmstadt. The three primary business sectors of Merck KGaA are life sciences, performance materials, and healthcare. Researchers in academia and applied disciplines, such as the biopharmaceutical industry, are principally served by the life sciences segment (47% of 2022 sales), which also offers laboratory supplies and services. Merck discovers, produces, and distributes branded drugs with major therapeutic concentrations in oncology, multiple sclerosis, and fertility in the healthcare industry (35%). The business provides speciality materials to make a range of goods, including semiconductors, flat-screen televisions, cars, and cosmetics, under its electronics section (18%). The E. Merck KG family publicly sold a portion of the business in 1995, which led to the current 30% public ownership of the business.
3. BrightPath Biotherapeutics: Established in 2003. Headquarters in Japan. A biopharmaceutical venture company is called BrightPath Biotherapeutics Co Ltd. It is working to create brand-new cancer immunotherapeutics. Two candidate drugs, ITK-1 and GRN-1201, which are now undergoing clinical trials, are among its offerings. In 2023, Artisan Bio. Inc., a precision genome engineering and drug discovery company, and BrightPath Biotherapeutics Co., Ltd. (TYO: 4594), a clinical stage biotechnology company focused on the development of cell therapies derived from invariant natural killer T (iNKT) cells, announced they had signed a research and licencing agreement to hasten the development of BrightPath's next-generation iNKT cell therapies.
4. Sellas: Established in 2012. Headquarters in the United States. A late-stage clinical biopharmaceutical business called SELLAS Life Sciences Group Inc. is dedicated to the creation of new therapies for a variety of cancer diseases. Galinpepimut-S, or GPS, a peptide immunotherapy targeted against the Wilms tumour 1 (WT1) antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor, are two of the company's current product candidates. To ensure that it can finance its present plan of developing its top oncology assets, a pair of cancer vaccines, Sellas Life Sciences is taking a number of "strategic options" into consideration.
5. BioLife Science: Created in 2012. The headquarters are in Australia. Creator of cancer immunotherapy targeted at HER-2-specific malignancies, including as breast and gastric cancer. A patented HER2 +ve cancer vaccine that induces a polyclonal antibody response to HER2/neu is one of its products, known as HER-Vaxx. Additionally, the business is working on B-cell peptide cancer vaccines and treatments. Research, development, and commercialization of oncolytic immunotherapies constitute its sole business segment. Sexton Biotechnologies (Aug 2021), Stirling Ultracold (May 2021), and SciSafe (Sep 2020) are the most recent acquisitions.
6. Boston Biomedical: Created in 2006. Headquarters in the United States. Creator of cutting-edge cancer therapies with the goal of considerably bettering patient outcomes. Drug discovery, external innovation partnerships, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), international clinical trials, regulatory affairs, and commercialization are just a few of the company's areas of expertise that give doctors access to cutting-edge treatments for cancer patients. Tolero Pharmaceuticals, Inc. and Boston Biomedical, Inc., two clinical-stage businesses researching innovative cancer treatments with U.S. roots and wholly owned subsidiaries of Sumitomo Dainippon Pharma Co., Ltd., merged today to establish Sumitomo Dainippon Pharma Oncology, Inc.
7. VAXON Biotech: Created in 2004. Headquarters in France, in Paris. Manufacturer of therapeutic vaccines intended to treat cancer. By encouraging the immune system to recognise and kill human cancer cells without hurting normal cells, the company's vaccines are designed to cure lung, stomach, prostate, breast, kidney, liver, and colorectal cancers. This enables patients to get treated for cancer and live a healthy life.
*Definition: Peptide-based cancer vaccines are generally made up of 20–30 amino acids that contain specific epitopes from antigens known to be highly immunogenic to elicit the desired immune response.
